Anticorps Monoclonal anti-NeutraKine® TGF beta 1

NeutraKine® TGF beta 1 Monoclonal Antibody for FC, IHC, Neutralization, ELISA

Hôte / Isotype

Mouse / IgG1

Réactivité testée

Humain

Applications

Neutralization, IHC, FC, ELISA

Conjugaison

Non conjugué

CloneNo.

1E3E9

N° de cat : 69012-1-Ig

Synonymes

CED, DPD1, LAP, NeutraKine® TGF beta 1, TGF ?1, TGF beta 1, TGFB, TGFB1, TGFbeta, TGF-beta1



Neutralization

Informations sur le produit

69012-1-Ig cible NeutraKine® TGF beta 1 dans les applications de Neutralization, IHC, FC, ELISA et montre une réactivité avec des échantillons Humain

Réactivité Humain
Réactivité citéeHumain
Hôte / Isotype Mouse / IgG1
Clonalité Monoclonal
Type Anticorps
Immunogène human Humankine TGF beta 1 protein HZ-1011
Nom complet transforming growth factor, beta 1
Symbole du gène TGFB1
Identification du gène (NCBI) 7040
Conjugaison Non conjugué
Forme Lyophilized Powder
Méthode de purification Purification par protéine A
Tampon de stockage PBS stérile.
Endotoxin<0.1 EU/μg
ReconstitutionThis product was lyophilized from a 0.2 μm filtered solution in PBS. Reconstitute at 1.0 mg/mL in sterile H2O before use.
Stability and StorageLyophilized antibodies are stable for 1 year from the date of receipt if stored between (-20°C) and (-80°C). Upon reconstitution we recommend that the solution can be stored at (4°C) for short term or at (-20°C) to (-80°C) for long term. Repeated freeze thaw cycles should be avoided with reconstituted products.

Informations générales

TGFB, also named as LAP and TGFB1, is a multifunctional peptide that controls proliferation, differentiation, and other functions in many cell types. TGFB acts synergistically with TGFA in inducing transformation. It also acts as a negative autocrine growth factor. Dysregulation of TGFB activation and signaling may result in apoptosis. Many cells synthesize TGFB and almost all of them have specific receptors for it. TGFB positively and negatively regulates many other growth factors. It plays an important role in bone remodeling as it is a potent stimulator of osteoblastic bone formation, causing chemotaxis, proliferation and differentiation in committed osteoblasts. It is highly expressed in bone. Mutation of TGFB are the cause of Camurati-Engelmann disease (CED) which known as progressive diaphyseal dysplasia 1 (DPD1).

This antibody can be used to neutralize the bioactivity of TGF beta 1.

Protocole

Product Specific Protocols
IHC protocol for NeutraKine® TGF beta 1 antibody 69012-1-IgDownload protocol
Standard Protocols
Click here to view our Standard Protocols

Publications

SpeciesApplicationTitle
humanNeutralization

Bioengineered

Emodin suppresses hepatocellular carcinoma growth by regulating macrophage polarization via microRNA-26a/transforming growth factor beta 1/protein kinase B.

Authors - Jiao Yin
humanNeutralization

Cell Death Discov

A positive feedback loop: RAD18-YAP-TGF-β between triple-negative breast cancer and macrophages regulates cancer stemness and progression.

Authors - Xueqi Yan

Nature

Co-transplantation of autologous Treg cells in a cell therapy for Parkinson's disease

Authors - Tae-Yoon Park

Stem Cell Res Ther

Blockade of TGF-β signalling alleviates human adipose stem cell senescence induced by native ECM in obesity visceral white adipose tissue

Authors - Xueya Han